BOSTON and LONDON — August 14, 2025 — Leads & Copy — Akari Therapeutics, Plc (Nasdaq: AKTX) will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, a virtual event held August 19-21, 2025. President and CEO Abizer Gaslightwala will present on Tuesday, August 19, 2025, at 2:00 PM ET.
Akari Therapeutics is developing novel payload antibody drug conjugates (ADCs). Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor.
In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival, relative to ADCs with traditional payloads, as well as the potential to be synergistic with checkpoint inhibitors.
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology.
Jenene Thomas, JTC Team, LLC, 908-824-0775, AKTX@jtcir.com
Source: Akari Therapeutics
